AstraZeneca PLC
AZNHealthcare|Drug Manufacturers - General|UK
$202.83
-0.66 (-0.32%)
DCF (FCF)
$71.68
Earnings Power
$36.18
Upcoming Data Readouts (36)
Oct 2026
Est. completion
P3AMI
DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
NCT05764057n=450
Oct 2026
Est. completion
Chronic Lymphocytic Leukaemia (CLL)
Retention Rate of Acalabrutinib in a Non-interventional Setting
NCT05645172n=137
Oct 2026
Est. completion
Nov 2026
Est. completion
P1P2Esophageal Adenocarcinoma
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
NCT02962063n=64
Nov 2026
Est. completion
P3Cutaneous Lupus Erythematosus
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737n=302
Dec 2026
Est. completion
P3Oropharyngeal Cancer
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
NCT04116047n=785
Dec 2026
Est. completion
P3Metastatic Castration-resistant Prostate Cancer (mCRPC)
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
NCT03903835n=750
Dec 2026
Est. completion
COPD
Leveraging Lung Cancer Screening to Optimize Screening Outcomes and COPD Management: COPD in LCS Registry
NCT06974981n=420
Dec 2026
Est. completion
Heart Failure With Preserved Ejection Fraction (HFPEF)
Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR
NCT07185100n=600
Dec 2026
Est. completion
Pan-tumor(NSCLC, GYN Cancers, BTC and UC)
A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients
NCT07404202n=2,100
Feb 2027
Est. completion
P1Refractory Systemic Lupus Erythematosus
A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus
NCT06530849n=18
Feb 2027
Est. completion
P2NSCLC
Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
NCT04716946n=13
Feb 2027
Est. completion
P3Diffuse Large B-Cell Lymphoma
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
NCT04529772n=611
Mar 2027
Est. completion
Lupus Erythematosus, Systemic
SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)
NCT05141201n=1,620
Mar 2027
Est. completion
P4Asthma
Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
NCT06422689n=1,511
May 2027
Est. completion
P2Metastatic Colorectal Cancer
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695n=120
Jun 2027
Est. completion
P3Heart Failure and Impaired Kidney Function
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652n=4,800
Sep 2027
Est. completion
P2Non-small Cell Lung Cancer (NSCLC)
Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC
NCT03667820n=41
Oct 2027
Est. completion
Oct 2027
Est. completion
P2Colorectal Cancer
Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
NCT07407465n=42
Awaiting Results (23)
Trials past primary completion date but still active — data readout may be imminent.
Aug 2026
P3
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
NCT04704934Aug 2026
P3
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252Apr 2026
P2
A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils
NCT06897748Apr 2026
P3
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
NCT04136171Mar 2026
P3
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
NCT03997123Mar 2026
P3
Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT05348577